The state of Connecticut currently has 37 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Recruiting
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D(Refered Phase II dose) of ATG-031.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas